CHC – The Cancer & Hematology Centers

 (SKL27969C001) SK Life Sciences

Description: A phase 1, open-label, multicenter, dose-finding study of SKL27969 in patients with advanced solid tumors, central nervous system (CNS) tumors, and hematologic malignancies


Target Patient Population:  All solid tumors

Study Design:  Drug is given orally currently for 3 days on, 4 days off